Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4807302 | 0.84 | PTGDR2 (0.46) | PTGDR2HTR2AALDH1A1CCR5SIGMAR1 | |
| SCHEMBL4807309 | 0.84 | PTGDR2 (0.46) | PTGDR2HTR2AALDH1A1CCR5SIGMAR1 | |
| SCHEMBL20780570 | 0.81 | HTR2A (0.65) | HTR2A | |
| SCHEMBL6202628 | 0.81 | HTR2A (0.51) | HTR2A | |
| SCHEMBL803784 | 0.81 | CCR5 (0.45) | PTGDR2HTR2ACCR5SIGMAR1OPRM1 | |
| Encyprate SCHEMBL122353 | 0.80 | L3MBTL1 (0.55) | ALDH1A1OPRM1AGER | |
| SCHEMBL13434086 | 0.80 | CCR5 (0.59) | ALDH1A1CCR5SIGMAR1 | |
| SCHEMBL803781 | 0.79 | HSD11B1 (0.46) | PTGDR2HTR2ACCR5SIGMAR1 | |
| SCHEMBL4964527 | 0.78 | CCR5 (0.47) | PTGDR2ALDH1A1GAACCR5SIGMAR1 | |
| SCHEMBL14104472 | 0.78 | HTR2A (0.41) | PTGDR2HTR2ATSHRCCR5SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | PTGDR2 154/4885HTR2A 475/4885ALDH1A1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.